Home > Back to Publisher > Report Information

Autoimmune Market Forecast to 2014

Cutting Edge Information
June 1, 2009
293 Pages - SKU: CIGQ2462816

Abstract Table of Contents Related Reports

Drive blockbuster revenue with autoimmune breakthroughs The autoimmune market is proving that the era of the blockbuster is not dead.

Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.

Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!

From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.

Delve into the data to:

Learn how brands and drug classes have fared: where they've succeeded - and failed
Show solid, objective evidence for your decision-making
Keep track of the competition
Get the latest on clinical trials
Uncover potential business development opportunities

Product Breakdown: • 43 Profiled Drugs; • 23 Biologics; • 20 Small Molecules; • 6 Indications
Brand Profile Components: • Product history; • Competitive and strategic positioning; • Market growth opportunities; • Sales projection charts; • Materiality charts; • Approval histories; • Market exclusivity and patent information (for approved drugs); • Clinical trial data tables
Company Profile Components: • Autoimmune market ranking; • Strengths analysis; • Growth areas analysis; • Key products breakdown
Chapter 1: Indications: • Psoriasis and Psoriatic Arthritis; • Rheumatoid arthritis; • Systemic Lupus Erythematosus and Lupus Nephritis; • Ulcerative colitis; • Crohn’s disease; • Multiple sclerosis
Chapter 2: Biologics: • B-cell inhibitors; • Rituxan; • Arzerra; • Lymphostat-B; • Ocrelizumab; • Atacicept; • TRU-015; • Interleukin inhibitors; • Actemra; • Stelara; • ACZ885; • Other biologics; • Campath; • Orencia; • Tysabri; • Prochymal; • Denosumab; • Dirucotide; • TNF inhibitors; • Cimzia; • Enbrel; • Humira; • Remicade; • Simponi; • Interferon betas; • Avonex; • Betaseron; • Rebif
Chapter 3: Small Molecules: • Immunomodulators; • Copaxone; • BG-12; • Fingolimod; • Laquinimod; • NSAIDs; • Arthrotec; • Celebrex; • 5-ASAs; • Asacol; • Lialda; • Pentasa; • Corticosteroids; • Entocort EC; • Taclonex; • Antimetabolites; • CellCept; • Cladibrine; • Teriflunomide; • JAK inhibitors; • CP-690,550; • INCB18424; • Other profiled small molecules; • Fampridine SR; • Apremilast; • AZD9056; • Firategrast
Chapter 4: Autoimmune Drug Manufacturer Profiles
The report details nine companies projected to have the top autoimmune franchises in their portfolios. What are their strategies for success? What products are they relying on? What challenges will they confront in the next few years?: • Abbott; • Roche; • Centocor (Johnson & Johnson); • Biogen Idec; • Amgen; • Pfizer; • Schering-Plough (Merck); • Merck KGaA; • Teva

Autoimmune Market Forecast to 2014

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service